Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)
GPCR · MARKET VIEW
Market view · as of Aug 24, 2026
Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.49
vs $-0.39 est · miss
52-wk position
40.6%
-47.7% vs 52w high · -0.1% 1mo
Price (last ~year)
Structure Therapeutics is advancing its oral GLP-1 candidate, aleniglipron, to Phase 3 trials following Phase 2b data showing 16.2% weight loss. As of June 30, 2026, the clinical-stage biopharmaceutical company reported a second-quarter net loss of $106.2 million, with $272.6 million in cash and $6.2 million in total debt. Shares closed at $49.09, representing 40.6% of the 52-week range, amid recent legal developments concerning a former executive's arbitration claim.
Valuation
- Market cap
- $3.50B
- P/B
- 2.59
- EV/EBITDA
- -13.46
- Beta
- -1.507
- Analyst target
- $104.77
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -20.2%
- ROA
- -14.9%
Price movement
- Last
- $49.09
- 1-month
- -0.1%
- 3-month
- +24.2%
- RSI (14)
- 52
- vs SMA200
- -8.6%
- 52-wk position
- 40.6% -47.7% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $0 | $-118.6M | $-106.2M | $-105.9M |
| 2026-03-31 | $0 | $-89.6M | $-76.2M | $-74.8M |
| 2025-12-31 | $0 | $24.0M | $33.0M | $33.6M |
| 2025-09-30 | $0 | $-73.8M | $-65.7M | $-65.3M |
Recent news
- Bullish Structure Therapeutics' oral GLP-1 drug shows 16.2% weight loss, advancing to Phase 3 with strong cash backing. · 2026-08-22
- Somewhat-Bearish Structure Therapeutics can't force chief financial officer’s harassment claim into arbitration · 2026-08-20
- Somewhat-Bullish Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR · 2026-08-20
- Neutral Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan · 2026-08-20
- Bullish J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100 · 2026-08-17
- Somewhat-Bearish Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen · 2026-08-17
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)